Epoch (epoetin beta biosimilar) / Roche - LARVOL DELTA

Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group (ASTRO 2025) - "ChI primarily consisted of R-CHOP (n=198, 82%) or R-EPOCH (n=19, 8%)... Results of this phase II study demonstrate high rates of local control with a lower dose of consolidation RT in a diverse population of patients with DLBCL/HGBL achieving a metabolic CR by post- ChI PET-CT. While guidelines currently recommend 30 Gy, this could be reduced to 20 Gy if high rates of local control are maintained with longer follow-up. A reduction in RT dose will decrease both acute and long-term toxicity."

P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Oncology

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics (ASH 2024) - "For > 90% of pts, the RDI was ≥90% for all individual components except vincristine (78%). There were 2 dose interruptions of doxorubicin (AMI [n=1], and poor performance status [n=1]), and 5 interruptions of glofit, (infection [n=3], hepatotoxicity [n=1], and rash [n=1])...With these regimens, PMR at EOI does not necessarily represent treatment failure, and cfDNA may be useful to further investigate outcomes in this setting. CRR and preliminary PFS is promising compared to historical outcomes in pts with HR LBCL."

Clinical • FDG PET • P2 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiomyopathy • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hepatology • Indolent Lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

Standardizing Stimulus Parameters for Noisy Galvanic Vestibular Stimulation. (PubMed, J Audiol Otol) - "Reports should specify the electrode polarity, passband and filter details, amplitude reference (peak, peak-to-peak, or root-mean-square), threshold procedures, and total stimulation dose...Priorities for future research include head-to-head tests of montage and frequency, individualized dose-response and after-effect mapping, stratification by baseline vestibular status, and mechanistic biomarkers tied to behavior. Standardized parameters and reporting will enable robust meta-analyses and faster clinical translation."

Journal • Review • CNS Disorders

Biomarkers. (PubMed, Alzheimers Dement) - "Automated CT brain segmentation guided by MRI-derived labels demonstrates clinically acceptable segmentation performance on untrained dementia cohort. nnU-Net is more resource-efficient and suitable for limited-resource settings, while MedNeXt has higher accuracy excelling in multi-orientation and multi-modal datasets. These findings validate the feasibility of using CT imaging with advanced segmentation frameworks to develop accessible neuroimaging tools for Alzheimer's and dementia research, addressing diagnostic challenges across diverse clinical contexts."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Dementia

Biomarkers. (PubMed, Alzheimers Dement) - "Plasma biomarkers of AD pathology, neuronal injury, and astrogliosis, measured at different life epochs (midlife vs. late-life) show distinct association patterns with subsequent changes in cognitive function across domains."

Biomarker • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • APOE • Aβ42 • GFAP • p-tau181

Basal EMG Amplitude in REM and NREM Sleep as a Predictor of Disease Progression in Isolated REM Sleep Behavior Disorder. (PubMed, Sleep) - "Elevated basal EMG amplitude during both REM and NREM sleep in iRBD patients shows potential as a prognostic marker, indicating muscle tone dysregulation beyond REM atonia loss and underscoring the need to consider broader sleep stages in iRBD evaluation."

Journal • Mental Retardation • Psychiatry • REM Sleep Behavior Disorder • Sleep Disorder

Biomarkers. (PubMed, Alzheimers Dement) - "Theta power and Theta rhythm duration are both linked to cognitive decline in MCI and AD but differ from healthy aging patterns. While Theta power reflects age-related changes, Theta rhythms duration may serve as a specific biomarker for disease progression in MCI and AD. These findings support the value of Rhythmicity analysis in EEG-based biomarkers of cognitive decline."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Developing Topics. (PubMed, Alzheimers Dement) - "Our findings suggest that addressing disparities in SDOH within the critical epoch of brain development encompassing infancy, childhood, and adolescence may hold the potential to reduce the likelihood of pathological brain changes associated with AD occurring later in life, including the accumulation of amyloid plaques, neuroinflammation, and axonal injury."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Aβ42 • GFAP

Stress Biomarkers in Young Adult University Students Before, During, and After the COVID-19 Pandemic: A Longitudinal Cohort Study. (PubMed, Cureus) - "The findings highlight the impact of long-term stressors on the biochemical balance of stress-hormones and neurotransmitters and the long-term biological and behavioral effects of the pandemic on university students, with potential consequences for their future somatic and mental health. Physical exercise emerges as an important protective factor against the effects of chronic stress, as does timely mental health monitoring and support."

Biomarker • Journal • Infectious Disease • Novel Coronavirus Disease

Terrestrial atmospheric ion implantation occurred in the nearside lunar regolith during the history of Earth's dynamo. (PubMed, Commun Earth Environ) - "This further suggests the history of the terrestrial atmosphere, spanning billions of years, could be preserved in buried lunar soils. Our results indicate that the elemental abundances of Apollo samples are highly sensitive to Earth's hydrodynamic escape boundary, which, at the time of ion implantation, was never smaller than 190 km."

Journal

R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL (ASH 2025) - "A total of 651 (46.8%) pts received 1L R-CHOP/R-EPOCH, 395 (28.4%) received 1L R-mini-CHOP, and 292(21.0%) received 1L Other Frail Regimens (mostly commonly including R-CVP, single agent R and R-bendamustine)... We present one of the largest real-world datasets of pts with DLBCL ≥ 80. Utilization of R-mini-CHOP resulted in comparable outcomes to more intensive regimens, with lower rates ofdiscontinuation due to toxicity. However, use of further intensity-modified frail regimens resulted inworse outcomes compared to R-mini-CHOP, despite similar baseline age and CCI scores."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor

Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP (ASH 2025) - "These data may helpinform clinical decision-making and provide a basis for designing future trials targeting this population,where R-miniCHOP could serve as a comparator arm. Funding: NU21-03-00411, U01 CA195568."

Clinical • B Cell Lymphoma • Heart Failure • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study (ASH 2025) - P=N/A | "In this large international analysis of patients with newly diagnosed THRLBCLcontemporaneously treated, we observed similar survival rates compared to DLBCL NOS treated with R-CHOP and intensive regimens. ECOG PS and the presence of B symptoms were independent factorsassociated with survival."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Rare Diseases • T Cell Histiocyte Rich Large B Cell Lymphoma

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis (ASH 2025) - "In patients that proceeded to ASCT, relapses occurred in 10pts (40%) with a 3 yr PFS and OS 56% and 83%, respectively.CAR-T was used as 2L in 20 pts (14%)- most commonly either axi-cel (N =7) or liso-cel (N = 8)...Other 2L treatments included pembrolizumab (N =3), brentuximabvedotin (BV) + nivolumab (N= 4) or single agent BV (N=2)... We report the largest cohort of pts with RR PMBCL treated in the rituximab era and thelargest number of PMBCL pts treated with 2L CAR-T. This is the first analysis, to our knowledge, to show astatistically significant benefit in PFS, ORR and CR rate of CAR-T compared to platinum salvage followedby HDT/ASCT as 2L treatment in a study of exclusively RR PMBCL pts. Our dataset was largely (93%)compromised of pts with primary refractory or early relapsing disease and provides support for usingCAR-T as 2L treatment in this high-risk subset of RR PMBCL patients."

Retrospective data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Transplantation

Anatomical localization-based analysis of de novo secondary cns lymphoma (ASH 2025) - "Among patients with available data, 14 (43.8%) were positivefor MYC rearrangement, 13 (54.2%) for BCL2 rearrangement, and 10 (45.5%) for BCL6 rearrangement.First-line regimens received by patients included MR-CHOP (n=18, 52.9%), DA-R-EPOCH (n=5, 14.7%),combined CODOX-M/IVAC (n=4, 11.7%), R-CHOP with intrathecal methotrexate (n=3, 8.8%), miscellaneoustherapies (n=3, 8.8%), and MRT (n=1, 2.9%)...DN-SCNSL can be anatomically classified into two subtypes: LM-DN-SCNSL and P-DN-SCNSL. While aprognostic trend favoring the parenchymal subtype was observed, the difference did not achievestatistical significance, a finding likely attributable to the small cohort size. This classification may holdclinical utility for guiding risk stratification, and larger studies are needed to validate these findings andidentify the most optimal treatments for each subtype of DN-SCNSL."

B Cell Lymphoma • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma • BCL2 • BCL6

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis (ASH 2025) - "Introduction The ECHELON-2 trial for newly diagnosed CD30+ peripheral T-cell lymphomas (PTCL) demonstratedsuperior overall survival with brentuximab vedotin plus chemotherapy (BV-CHP) compared to CHOP.However, total enrollment was restricted to only 30% of patients with non-anaplastic large cell lymphoma(ALCL) histologies and was not powered to analyze survival benefits in this cohort...Adding to this uncertainty, CHOP plus etoposide (CHOEP)remains a standard regimen for many non-ALCL PTCL histologies for patients <60 years of age...ASCT forpatients in CR offered superior outcomes, supporting this strategy regardless of the frontline regimen,recognizing the limitations of non-randomized, retrospective analyses. Novel-CHOP regimensdemonstrated encouraging survival, and clinical trials should maintain priority over standard regimensfor patients with CD30+ (1-10%) PTCL-NOS and PTCL-TFH."

Retrospective data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma (ASH 2025) - "MethodsWe harmonized and pooled data from 6,941 patients with newly diagnosed systemic LBCL treated with R-CHOP-like regimens (R-CHOP, R-miniCHOP, DA-EPOCH-R, R-CHOEP, R-CHOP+X) with complete IPI datafrom three prospective cohorts: NiHiL (Czech Republic, n=4,590; 2010–2023), LEO (USA, n=1,789; 2015–2020), and MER (USA, n=562; 2010–2015)...These findings underscore the need for more individualized prognostic tools forLBCL patients. Funding: NU21-03-00411, P50 CA97274, U01 CA195568, Charles University Haematology-OncologyCooperatio Program."

Clinical • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CA724 • CA9

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States (ASH 2025) - "This is the first U.S.-based real-world analysis of Glofit-GemOx, including more U.S. pts than the STARGLOtrial, appear to demonstrate comparable response rates, potentially supporting its use as both bridgingand destination therapy. Notable toxicities, including CRS, were observed, with 2 possible treatment-related deaths, with plausible alternate non-treatment related causes. Favorable responses were seen inbridging therapy and high-risk subgroups (transformed, HGBCL) which were excluded in the STARGLOtrial."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Influenza • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Respiratory Diseases • CD20

Behavioral and Electrophysiological Arousal from Sleep with Intralaminar Thalamic Stimulation: Titration of Parameters for Epilepsy Therapy (AES 2025) - "These findings indicate that stimulation of the CL nucleus of the thalamus reliably elicited transient arousal from sleep across patients, as evidenced by reductions in delta and theta power and concurrent increased physiological and behavioral markers of arousal. These findings highlight the CL as a critical node in the regulation of human arousal and suggest its potential as a therapeutic target for neuromodulation of impaired consciousness in epilepsy and other disorders."

CNS Disorders • Epilepsy

Incidence of Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study (ASH 2023) - "16 patients received intrathecal (IT) chemotherapy (methotrexate and/or cytarabine) for CNS prophylaxis, 3 with R-CHOP and 13 with R-DA-EPOCH...The patient was treated with HD-MTX, temozolomide and rituximab for CNS relapse, and subsequently received multiple therapies for systemic disease including R-DHAP, R-ICE, and died 17 months after CNS relapse...CNS relapse was associated with poor survival despite aggressive treatment approaches. Novel approaches utilizing biological risk factors for CNS relapse, such as circulating tumor DNA, are needed to identify patients with CNS relapse."

Retrospective data • B Cell Lymphoma • Classical Hodgkin Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma (ASH 2023) - "Patients requiring early initiation of therapy for aggressive B-cell lymphoma represent a distinct population of patients with more aggressive clinical features and inferior outcomes. In patients with longer DTI, high grade subtypes had similar outcomes to DLBCL, NOS. Efforts should be made to include patients with anticipated short DTI in clinical trials and translational studies to fully capture the spectrum of patients with aggressive B-cell lymphoma."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium (ASH 2023) - "Patterns of care in Transformed FL are heterogeneous and vary greatly in intensity. These data confirm previous reports that age, early HT, and any systemic therapies prior to HT are negative prognostic indicators for OS. At HT elevated LDH, low hemoglobin, POD24 status, poor performance status, and HT to HGBCL were associated with poor outcomes following HT."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study (ASH 2023) - P=N/A | "The most common 1st line chemotherapy regimens overall were CHOP-based (N=506, 70%), including 60% receiving CHOP-like chemotherapy in both MER and LEO cohorts (CHOP [N=268, 37%], CHOEP [N=91, 13%] or EPOCH [N=75, 10%]), and 16% with CHOP-like in combination with novel agents in LEO cohort (BV+ [N=41, 9.3%], azacitidine+ [N=11, 2.5%], pralatrexate+ [N=10, 2.3%], lenalidomide+ [N=8, 1.9%]) (Table 1)...Outcomes continue to mature with longitudinal follow-up and ongoing accrual, which poise to shape benchmarks in the contemporary era. The lack of benefit of etoposide adding to CHOP induction and poor overall survival of non-ALCL subtypes underscores the unmet need of therapeutic breakthrough for non-ALCL frontline treatment, particularly through clinical trials with biomarker-guided approaches incorporating novel agents."

Clinical • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma (ASH 2023) - "Twenty-six (81%) were treated with a systemic therapy, mainly CHOP-backbone therapy (R-CHOP n=13, CHOP n=4, R-EPOCH n=3, lenalidomide-R-CHOP n=1)... In this North American prospective cohort of mainly non-Hispanic White patients, we found a low cumulative incidence of HT in MZL of 2.9% and 4.5% at 5- and 10-year, which was consistent with the Finnish findings (Kalashnikov et al., 2023). At HT, age was associated with OS and there was a high response rate to CHOP-backbone therapies."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A pilot study using actigraphy to examine activity performance and its relationship with activity capacity in adults with facioscapulohumeral muscular dystrophy. (PubMed, J Neuromuscul Dis) - "Correlations were found between total MVPA and 10mw/r (ρ=-0.720, p = 0.006) and TUG-comfortable (ρ=-0.720, p = 0.006), and between maximum step count and several functional measures.ConclusionThis pilot study provides insights into activity performance and its relationship with capacity in a small cohort of adults with FSHD. Total MVPA and maximum step count appear most informative for evaluating activity performance; larger studies are needed to confirm findings and assess psychometric properties of these metrics."

Journal • Muscular Dystrophy